The Institute for Clinical and Economic Review (ICER) is looking ahead to ensure its upcoming cost effectiveness/value analysis of drugs for non-small cell lung cancer remains relevant: the group plans to include Roche’s PD-L1 inhibitor Tecentriq (atezolizumab), which is still under FDA review for the indication.
According to a draft “scoping” document released June 21, ICER will evaluate Tecentriq along with two other immunotherapies targeting the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?